Targeting CD44v6 expressed in head and neck squamous cell carcinoma: Preclinical characterization of an 111In-labeled monoclonal antibody

Tumor Biology

Volumn 29, Issue 3, 2008, Pages 137-144

  Sandström, Karl ^a,b   Nestor, Marika ^a   Ekberg, Tomas ^a   Engström, Mats ^a   Anniko, Matti ^a   Lundqvist, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody; CD44v6; HNSCC; Imaging; Indium 111

Indexed keywords

CD44V6 ANTIGEN; CHELATING AGENT; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY HUA33 IN 111; MONOCLONAL ANTIBODY IN 111; MONOCLONAL ANTIBODY U36 IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BAGG ALBINO MOUSE; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG UPTAKE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SCINTILLATION CAMERA; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

EID: 46449118300     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000143399     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL: Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
4. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-762.
5. Czernin J, Allen-Auerbach M, Schelbert HR: Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48(suppl 1):78S-88S.
6. Stern M, Herrmann R: Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005;54:11-29.
7. Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, et al: Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43:245-253.
8. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, et al: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 1996;148:453-463.
9. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
10. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010.
11. Borjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, et al: Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006;12:2133-2140.
12. Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH: Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996;68:520-527.
13. van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brakenhoff RH: Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;82:837-845.
14. Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, et al: MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-4390.
15. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, et al: Safety and biodistribution of 99mtechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 2000;6:3046-3055.
16. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GA: Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1:591-598.
17. Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA: Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 1995;40:191-200.
18. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H: Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 2000;46(suppl):S27-S32.
19. Persson M, Tolmachev V, Andersson K, Gedda L, Sandstrom M, Carlsson J: [(177)Lu]-pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32:1457-1462.
20. van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA: High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80(12 suppl):2360-2370.
21. Duncan JR, Behr TM, DeNardo SJ: Intracellular fate of radiometals. J Nucl Med 1997;38:829.
22. Duncan JR, Welch MJ: Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 1993;34:1728-1738.
23. Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K, Lundqvist H: Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging 2007;34:1376-1387.
24. Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, et al: In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1296-1304.
25. Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G, Anniko M, et al: Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecabo-rate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 2003;14:805-810.
26. 111In for imaging human breast cancer. J Nucl Med 2000;41:903-911.
27. DeNardo SJ, Zhong GR, Salako Q, Li M, De-Nardo GL, Meares CF: Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. J Nucl Med 1995;36:829-836.
28. de Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MW, Castelijns JA, et al: The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nucl Med 1998;25:1562-1565.
29. Moldoveanu Z, Epps JM, Thorpe SR, Mestecky J: The sites of catabolism of murine monomeric IgA. J Immunol 1988;141:208-213.